PROJECT 5 Hazardous waste sites contain complex mixtures of a wide variety of toxic chemicals that contaminate and linger in the environment. The acute toxicities of numerous Superfund (SF) chemicals have been extensively investigated; however, further studies are needed to determine their chronic effects on human health. Several SF chemicals (e.g. naphthalene, PCBs, and CCl4), which are found in environmental samples from the Yurok Tribe of the Klamath River basin, and in California air, have been shown to induce endoplasmic reticulum (ER) stress in cultured cells. Furthermore, in animal models, long-term exposure to CCl4 leads to ER stress in tissues, resulting in fibrosis and organ damage. Thus, the central hypothesis for this project is that chronic exposure to xenobiotics leads to ER stress that then contributes to chronic inflammation, tissue fibrosis and eventual organ failure. Based on the novel concept that the magnitude of ER stress is proportional to the amount of chronic exposure to chemicals, and monitoring ER stress will help predict resulting biological effects, the long term goal of this project is to develop a high-content and medium throughput bioassay to test the potential of SF chemicals to induce ER stress (Aim IIIA), and a biomarker of ER stress-associated biological effects for bio-fluid analysis (Aim IIIB). Toward these objectives, cell-based assays (Aim I) will be used to understand the mechanisms by which exposure to environmental toxins leads to ER stress. In addition, in animal models (Aim II, with Project 4), Project 5 will evaluate the effects of chronic exposure to hazardous chemicals on ER stress, and test if seric oxylipids are surrogate biomarkers for ER stress (with Cores A and B). The methodology developed and data obtained from the cell cultures and animal models will be directly translated in developing biomarker assays (Aim IIIA and B; with Projects 2 and 3, and Cores A and B). Finally, research findings will be utilized to serve the community at large by testing field samples collected from the Klamath River basin, the Central Valley and the Sierra Nevada foothills in California, and at or around SF-sites across the U.S.
(Aim III C with Project 1, Cores B, C and D), as well as transferring to the scientists of the Yurok Tribe Environmental Program (with Core E). Accordingly, the overall goals of this project are to: 1) test lipid mediators as potential diagnostic biomarkers for the magnitude of ER stress response that often contributes to organ damage, 2) develop fast, inexpensive and reliable new cell-based bioassays to detect, assess and quantitate the effects of hazardous substances on ER stress, 3) provide new mechanistic insights into the effects of chronic exposure to SF chemicals on ER stress and fibrotic diseases, 4) develop biomarkers assays for bio-fluids for the quantification of tissue-specific effects of xenobiotics on ER stress, and 5) translate our findings by assessing risk on human health, by analyzing field samples.

Public Health Relevance

PROJECT 5 Within the goals of the UC Davis Superfund Center, this project will investigate new mechanistic insights into the effects of chronic exposure of Superfund (SF) chemicals on endoplasmic reticulum (ER) stress, which leads to fibrosis and organ damage. Recent and exciting data demonstrate that exposure to xenobiotics perturbs the levels of P450-generated lipid mediators, which directly affect the pathological development of ER stress. Thus, this project will directly test the novel hypothesis that plasma lipid mediators may represent a surrogate biomarker for ER stress following chronic xenobiotic exposure, as well as developing a new cell- based bioassay for quantitation of pro-ER stress environmental toxicants in field samples.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Hazardous Substances Basic Research Grants Program (NIEHS) (P42)
Project #
5P42ES004699-32
Application #
9917789
Study Section
Special Emphasis Panel (ZES1)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
32
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Hill 3rd, Thomas; Rice, Robert H (2018) DUOX expression in human keratinocytes and bronchial epithelial cells: Influence of vanadate. Toxicol In Vitro 46:257-264
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475

Showing the most recent 10 out of 1149 publications